{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:48:33Z","timestamp":1792633713715,"version":"4.5.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070747"],"award-info":[{"award-number":["32070747"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2022NSFSC0771"],"award-info":[{"award-number":["2022NSFSC0771"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118090","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:31:05Z","timestamp":1755930665000},"page":"118090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Cyclin-dependent kinase 1 (CDK1) in cancers: from upstream regulation to downstream substrates and therapeutic inhibitors"],"prefix":"10.1016","volume":"299","author":[{"given":"Ji","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-6845","authenticated-orcid":false,"given":"Chenghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118090_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib2","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1242\/jcs.115.12.2461","article-title":"From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner?","volume":"115","author":"Doree","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2025.118090_bib3","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/ncomms7769","article-title":"CDK1 structures reveal conserved and unique features of the essential cell cycle CDK","volume":"6","author":"Brown","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118090_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nature06046","article-title":"Cdk1 is sufficient to drive the mammalian cell cycle","volume":"448","author":"Santamar\u00eda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118090_bib5","doi-asserted-by":"crossref","first-page":"26739","DOI":"10.1073\/pnas.2010885117","article-title":"Structural basis for CDK7 activation by MAT1 and Cyclin H","volume":"117","author":"Peissert","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118090_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/1573406415666190626113900","article-title":"Inhibitors of cyclin-dependent kinase 1\/2 for anticancer treatment","volume":"16","author":"Mou","year":"2020","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1083\/jcb.200912084","article-title":"The APC\/C recruits cyclin B1-Cdk1-Cks in prometaphase before D box recognition to control mitotic exit","volume":"190","author":"van Zon","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nsmb.2707","article-title":"Cks confers specificity to phosphorylation-dependent CDK signaling pathways","volume":"20","author":"McGrath","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib9","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41416-023-02468-8","article-title":"The Cyclin-dependent kinase 1: more than a cell cycle regulator","volume":"129","author":"Massacci","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118090_bib10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bbapap.2009.10.002","article-title":"Recent developments in cyclin-dependent kinase biochemical and structural studies","volume":"1804","author":"Echalier","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2025.118090_bib11","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cyclins and CKIs: roles beyond cell cycle regulation","volume":"140","author":"Lim","year":"2013","journal-title":"Development"},{"key":"10.1016\/j.ejmech.2025.118090_bib12","article-title":"CDK1 acts as a prognostic biomarker associated with immune infiltration in pan-cancer, especially in gastrointestinal tumors","author":"Shen","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41698-023-00407-7","article-title":"Targeting CDK1 in cancer: mechanisms and implications","volume":"7","author":"Wang","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejmech.2025.118090_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112005","article-title":"CDK1 bridges NF-kappaB and beta-catenin signaling in response to H. pylori infection in gastric tumorigenesis","volume":"42","author":"Zhu","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118090_bib15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cas.15347","article-title":"NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1","volume":"114","author":"He","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.118090_bib16","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.7150\/jca.69216","article-title":"DDX21 interacts with WDR5 to promote colorectal cancer cell proliferation by activating CDK1 expression","volume":"13","author":"Lu","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118090_bib17","article-title":"Inhibition of CDK1 overcomes oxaliplatin resistance by regulating ACSL4-mediated ferroptosis in colorectal cancer","volume":"10","author":"Zeng","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2025.118090_bib18","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1038\/s41388-019-0861-z","article-title":"KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner","volume":"38","author":"Qian","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib19","article-title":"N4-Acetylcytidine-Mediated CD2BP2-DT drives YBX1 phase separation to stabilize CDK1 and promote breast cancer progression","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2025.118090_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbrc.2019.12.058","article-title":"Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1","volume":"523","author":"Li","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118090_bib21","first-page":"2066","article-title":"GRIK3 deficiency promotes non-small cell lung cancer progression by the regulation of the UBE2C\/CDK1\/Wnt signaling pathway","volume":"13","author":"Liu","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13046-023-02781-3","article-title":"Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis","volume":"42","author":"Han","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41419-024-06569-x","article-title":"OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway","volume":"15","author":"Ci","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118090_bib24","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-10-2453","article-title":"Identification of N-terminally truncated stable nuclear isoforms of CDC25B that are specifically involved in G2\/M checkpoint recovery","volume":"71","author":"Jullien","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib25","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1038\/sj.onc.1205870","article-title":"Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role for pEg3 in cell cycle regulation","volume":"21","author":"Davezac","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib26","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1038\/onc.2017.287","article-title":"KCTD12 promotes tumorigenesis by facilitating CDC25B\/CDK1\/Aurora A-dependent G2\/M transition","volume":"36","author":"Zhong","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib27","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.celrep.2019.09.087","article-title":"NFE2L3 controls Colon cancer cell growth through regulation of DUX4, a CDK1 inhibitor","volume":"29","author":"Bury","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118090_bib28","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1038\/s41467-025-57538-7","article-title":"Copper is essential for cyclin B1-mediated CDK1 activation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"2089","key":"10.1016\/j.ejmech.2025.118090_bib29","article-title":"Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118090_bib30","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79128","article-title":"S6K1 phosphorylates Cdk1 and MSH6 to regulate DNA repair","volume":"11","author":"Amar-Schwartz","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118090_bib31","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/0008-5472.CAN-23-4130","article-title":"Low-molecular weight cyclin E confers a vulnerability to PKMYT1 inhibition in triple-negative breast cancer","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib32","doi-asserted-by":"crossref","first-page":"D631","DOI":"10.1093\/nar\/gkac883","article-title":"SIGNOR 3.0, the SIGnaling network open resource 3.0: 2022 update","volume":"51","author":"Lo Surdo","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-024-01767-7","article-title":"The two sides of chromosomal instability: drivers and brakes in cancer","volume":"9","author":"Hosea","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118090_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112344","article-title":"G2\/M-Phase checkpoint adaptation and micronuclei formation as mechanisms that contribute to genomic instability in human cells","volume":"18","author":"Kalsbeek","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118090_bib35","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ng1861","article-title":"A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers","volume":"38","author":"Carter","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2025.118090_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118090_bib37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nrc2249","article-title":"Oncogenes and tumour suppressors take on centrosomes","volume":"7","author":"Fukasawa","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118090_bib38","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1038\/sj.onc.1209310","article-title":"Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication","volume":"25","author":"Duensing","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib39","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1038\/onc.2008.161","article-title":"Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells","volume":"27","author":"Hanashiro","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1083\/jcb.200702034","article-title":"An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells","volume":"178","author":"Hochegger","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib41","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/ncb2287","article-title":"Cdk1-phosphorylated CUEDC2 promotes spindle checkpoint inactivation and chromosomal instability","volume":"13","author":"Gao","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib42","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35337","article-title":"High levels of histones promote whole-genome-duplications and trigger a Swe1(WEE1)-dependent phosphorylation of Cdc28(CDK1)","volume":"7","author":"Maya Miles","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118090_bib43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2009.06.036","article-title":"Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage","volume":"35","author":"Johnson","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nature03404","article-title":"CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair","volume":"434","author":"Esashi","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118090_bib45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.15698\/mic2018.07.639","article-title":"Shepherding DNA ends: Rif1 protects telomeres and chromosome breaks","volume":"5","author":"Fontana","year":"2018","journal-title":"Microb. Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/acel.12466","article-title":"Rif1 and Exo1 regulate the genomic instability following telomere losses","volume":"15","author":"Xue","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib47","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","article-title":"DNA repair network analysis reveals Shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity","volume":"173","author":"Gupta","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib48","doi-asserted-by":"crossref","first-page":"13374","DOI":"10.1073\/pnas.1903418116","article-title":"An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication","volume":"116","author":"Moiseeva","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118090_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111836","article-title":"Increased replication origin firing links replication stress to whole chromosomal instability in human cancer","volume":"41","author":"Bohly","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118090_bib50","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1083\/jcb.201806057","article-title":"CDK1-mediated phosphorylation at H2B serine 6 is required for mitotic chromosome segregation","volume":"218","author":"Seibert","year":"2019","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib51","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/MCB.00731-10","article-title":"Cdk1\/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity","volume":"30","author":"Matthess","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.molcel.2007.03.019","article-title":"Phosphorylation of caspase-9 by CDK1\/cyclin B1 protects mitotic cells against apoptosis","volume":"26","author":"Allan","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.devcel.2014.03.012","article-title":"Cyclin B1\/Cdk1 coordinates mitochondrial respiration for cell-cycle G2\/M progression","volume":"29","author":"Wang","year":"2014","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib54","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.celrep.2015.11.015","article-title":"CDK1 enhances mitochondrial bioenergetics for radiation-induced DNA repair","volume":"13","author":"Qin","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118090_bib55","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jmcb\/mjs062","article-title":"CyclinB1\/Cdk1 phosphorylates mitochondrial antioxidant MnSOD in cell adaptive response to radiation stress","volume":"5","author":"Candas","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib56","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/1535-7163.MCT-15-0017","article-title":"CDK1-Mediated SIRT3 activation enhances mitochondrial function and tumor radioresistance","volume":"14","author":"Liu","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118090_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012341","article-title":"Cyclin B1\/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response","volume":"5","author":"Nantajit","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118090_bib58","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.devcel.2019.11.012","article-title":"Low-level saturated fatty acid palmitate benefits liver cells by boosting mitochondrial metabolism via CDK1-SIRT3-CPT2 Cascade","volume":"52","author":"Liu","year":"2020","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118090_bib60","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.3390\/ijms23073691","article-title":"Metazoans and intrinsic apoptosis: an evolutionary analysis of the Bcl-2 family","volume":"23","author":"Suraweera","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118090_bib61","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/emboj.2010.112","article-title":"Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest","volume":"29","author":"Harley","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118090_bib62","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41388-017-0108-9","article-title":"Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer","volume":"37","author":"Saatci","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib63","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cbin.10259","article-title":"CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2\/Bax family proteins during treatment with microtubule interfering agents","volume":"38","author":"Zhou","year":"2014","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejmech.2025.118090_bib64","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib65","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","article-title":"Ferroptosis: machinery and regulation","volume":"17","author":"Chen","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2025.118090_bib66","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","article-title":"Transcriptional regulation and its misregulation in disease","volume":"152","author":"Lee","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/jmcb\/mjac074","article-title":"The ARTS of p53-dependent mitochondrial apoptosis","volume":"14","author":"Hao","year":"2023","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118090_bib69","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib70","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1073\/pnas.87.12.4766","article-title":"Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2","volume":"87","author":"Bischoff","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118090_bib71","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41419-022-05254-1","article-title":"Circ_CEA promotes the interaction between the p53 and cyclin-dependent kinases 1 as a scaffold to inhibit the apoptosis of gastric cancer","volume":"13","author":"Yuan","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118090_bib72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ng1070","article-title":"iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human","volume":"33","author":"Bergamaschi","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2025.118090_bib73","doi-asserted-by":"crossref","first-page":"17470","DOI":"10.1073\/pnas.1909393116","article-title":"iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition","volume":"116","author":"Chen","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118090_bib74","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41418-023-01168-3","article-title":"p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer","volume":"30","author":"Miller","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2025.118090_bib75","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccell.2017.09.008","article-title":"iASPP is an antioxidative factor and drives cancer growth and drug resistance by competing with Nrf2 for Keap1 binding","volume":"32","author":"Ge","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib76","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ccr.2013.03.013","article-title":"Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1\/CDK1-phosphorylated nuclear iASPP","volume":"23","author":"Lu","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib77","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1038\/sj.onc.1210337","article-title":"p63 and p73 in human cancer: defining the network","volume":"26","author":"Deyoung","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib78","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00018-017-2666-y","article-title":"A double dealing tale of p63: an oncogene or a tumor suppressor","volume":"75","author":"Chen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.118090_bib79","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.3390\/ijms23137385","article-title":"CDK1 promotes epithelial-mesenchymal transition and migration of head and neck squamous carcinoma cells by repressing \u0394Np63\u03b1-Mediated transcriptional regulation","volume":"23","author":"Chen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118090_bib80","doi-asserted-by":"crossref","first-page":"27421","DOI":"10.1074\/jbc.M300251200","article-title":"Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73","volume":"278","author":"Gaiddon","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib81","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41388-023-02598-6","article-title":"Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction","volume":"42","author":"Tong","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib82","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.biopha.2018.08.116","article-title":"An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers","volume":"107","author":"Chohan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118090_bib83","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1002\/j.1460-2075.1991.tb05006.x","article-title":"The retinoblastoma protein is phosphorylated on multiple sites by human cdc2","volume":"10","author":"Lees","year":"1991","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118090_bib84","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0092-8674(94)90522-3","article-title":"Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19 kDa protein","volume":"78","author":"Fagan","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib85","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13046-022-02412-3","article-title":"NCAPD3 enhances Warburg effect through c-myc and E2F1 and promotes the occurrence and progression of colorectal cancer","volume":"41","author":"Jing","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib86","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1038\/s41467-024-47680-z","article-title":"The pRb\/RBL2-E2F1\/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry\/exit by paracrine mechanisms","volume":"15","author":"Chang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118090_bib87","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.molcel.2022.07.014","article-title":"Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression","volume":"82","author":"Sanidas","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib88","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41586-019-1172-9","article-title":"RB constrains lineage fidelity and multiple stages of tumour progression and metastasis","volume":"569","author":"Walter","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118090_bib89","article-title":"Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118090_bib90","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1038\/onc.2008.104","article-title":"CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor","volume":"27","author":"Liu","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s10020-021-00302-6","article-title":"Phosphorylation of islet-1 serine 269 by CDK1 increases its transcriptional activity and promotes cell proliferation in gastric cancer","volume":"27","author":"Shi","year":"2021","journal-title":"Mol Med"},{"key":"10.1016\/j.ejmech.2025.118090_bib92","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1158\/0008-5472.CAN-18-0330","article-title":"CDK1 interacts with Sox2 and promotes tumor initiation in human Melanoma","volume":"78","author":"Ravindran Menon","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib93","doi-asserted-by":"crossref","first-page":"15028","DOI":"10.1074\/jbc.M117.796284","article-title":"Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity","volume":"292","author":"Zeng","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib94","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/gutjnl-2019-320441","article-title":"CDK1\/2\/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer","volume":"70","author":"Huang","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2025.118090_bib95","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.4161\/cc.26930","article-title":"CDK1 stabilizes HIF-1\u03b1 via direct phosphorylation of Ser668 to promote tumor growth","volume":"12","author":"Warfel","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2025.118090_bib96","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2025.118090_bib97","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(03)01074-2","article-title":"Back to the future with ubiquitin","volume":"116","author":"Pickart","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib98","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/35056563","article-title":"Themes and variations on ubiquitylation","volume":"2","author":"Weissman","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib99","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/emmm.201202341","article-title":"CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer","volume":"5","author":"Cepeda","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118090_bib100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.adq7408","article-title":"ASB7 is a negative regulator of H3K9me3 homeostasis","volume":"389","author":"Zhou","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118090_bib101","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41388-022-02234-9","article-title":"iASPP is essential for HIF-1\u03b1 stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation","volume":"41","author":"Zhao","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib102","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41418-023-01128-x","article-title":"PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions","volume":"30","author":"Chen","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2025.118090_bib103","article-title":"Phosphorylation of USP29 by CDK1 governs TWIST1 stability and oncogenic functions","volume":"10","author":"Guan","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2025.118090_bib104","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.apsb.2025.02.014","article-title":"CDK1-mediated phosphorylation of USP37 regulates SND1 stability and promotes oncogenesis in colorectal cancer","volume":"15","author":"Wu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118090_bib105","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1073\/pnas.92.8.3454","article-title":"Phosphorylation of ubiquitin-activating enzyme in cultured cells","volume":"92","author":"Cook","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118090_bib106","doi-asserted-by":"crossref","first-page":"10895","DOI":"10.1074\/jbc.272.16.10895","article-title":"Identification of a region within the ubiquitin-activating enzyme required for nuclear targeting and phosphorylation","volume":"272","author":"Stephen","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib107","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/emboj\/21.8.2009","article-title":"Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation","volume":"21","author":"Sarcevic","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118090_bib108","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.4161\/cc.26278","article-title":"Ubp-M serine 552 phosphorylation by cyclin-dependent kinase 1 regulates cell cycle progression","volume":"12","author":"Xu","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2025.118090_bib109","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(89)90796-4","article-title":"EGF induces biphasic S6 kinase activation: late phase is protein kinase C-dependent and contributes to mitogenicity","volume":"57","author":"Susa","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib110","doi-asserted-by":"crossref","first-page":"15077","DOI":"10.1074\/jbc.273.24.15077","article-title":"Cdc2-cyclin B phosphorylates p70 S6 kinase on Ser411 at mitosis","volume":"273","author":"Papst","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib111","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1078-0432.CCR-08-1543","article-title":"Phospho-p70S6K\/p85S6K and cdc2\/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy","volume":"15","author":"Zhao","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118659","article-title":"GSK-3\u03b2 in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer","volume":"1867","author":"Lin","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib113","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cdd.2016.84","article-title":"CDK1-PDK1-PI3K\/Akt signaling pathway regulates embryonic and induced pluripotency","volume":"24","author":"Wang","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2025.118090_bib114","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.7150\/thno.25487","article-title":"Blocking CDK1\/PDK1\/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma","volume":"8","author":"Wu","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.118090_bib115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2012.09.002","article-title":"Gravin is a transitory effector of polo-like kinase 1 during cell division","volume":"48","author":"Canton","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.118090_bib116","doi-asserted-by":"crossref","first-page":"14761","DOI":"10.1074\/jbc.M116.722751","article-title":"Ajuba phosphorylation by CDK1 promotes cell proliferation and tumorigenesis","volume":"291","author":"Chen","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib117","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118090_bib118","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aao0535","article-title":"Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism","volume":"357","author":"Chiba","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118090_bib119","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature08283","article-title":"An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA","volume":"461","author":"Maida","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118090_bib120","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41467-020-15289-7","article-title":"CDK1 dependent phosphorylation of hTERT contributes to cancer progression","volume":"11","author":"Yasukawa","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118090_bib121","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899395","article-title":"CDK1-mediated BCL9 phosphorylation inhibits clathrin to promote mitotic Wnt signalling","volume":"37","author":"Chen","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118090_bib122","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/0008-5472.CAN-18-2486","article-title":"Cell-cycle-dependent phosphorylation of PRPS1 fuels nucleotide synthesis and promotes tumorigenesis","volume":"79","author":"Jing","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib123","doi-asserted-by":"crossref","first-page":"21233","DOI":"10.1074\/jbc.M109.082875","article-title":"Mucin 21\/epiglycanin modulates cell adhesion","volume":"285","author":"Yi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib124","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/s41388-024-03102-4","article-title":"GDNF-induced phosphorylation of MUC21 promotes pancreatic cancer perineural invasion and metastasis by activating RAC2 GTPase","volume":"43","author":"Chen","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm990256j","article-title":"Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation","volume":"43","author":"Sielecki","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib126","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/156800908783497131","article-title":"Inhibitors of cyclin dependent kinases: useful targets for cancer treatment","volume":"8","author":"Sharma","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2025.118090_bib127","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2025.118090_bib128","first-page":"1143","article-title":"Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy","volume":"9","author":"Sedlacek","year":"1996","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2025.118090_bib129","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118090_bib130","first-page":"307","article-title":"Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial","volume":"9","author":"Karp","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib131","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib132","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CCO.0b013e3282efb9da","article-title":"Flavopiridol in the treatment of chronic lymphocytic leukemia","volume":"19","author":"Christian","year":"2007","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118090_bib133","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/13543784.2017.1384814","article-title":"Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia","volume":"26","author":"Robak","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.118090_bib134","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/1535-7163.MCT-06-0614","article-title":"P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models","volume":"6","author":"Joshi","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118090_bib135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1476-4598-11-77","article-title":"P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines","volume":"11","author":"Shirsath","year":"2012","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118090_bib136","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1432-1033.1994.00771.x","article-title":"Inhibition of cyclin-dependent kinases by purine analogues","volume":"224","author":"Vesel\u00fd","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2025.118090_bib137","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1023\/A:1008115004986","article-title":"Structure-based design of potent CDK1 inhibitors derived from olomoucine","volume":"14","author":"Furet","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2025.118090_bib138","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib139","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118090_bib140","article-title":"A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies","volume":"26","author":"Shapiro","year":"2008","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2025.118090_bib141","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118090_bib142","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"11","author":"Nemunaitis","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118090_bib143","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1158\/0008-5472.CAN-03-0110","article-title":"The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway","volume":"64","author":"Whittaker","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib144","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ejca.2010.08.001","article-title":"Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies","volume":"46","author":"Le Tourneau","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118090_bib145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118090_bib146","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1158\/1535-7163.MCT-08-0080","article-title":"N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine","volume":"7","author":"Bettayeb","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118090_bib147","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/onc.2008.191","article-title":"CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases","volume":"27","author":"Bettayeb","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib148","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/0008-5472.CAN-05-2507","article-title":"Discovery and evaluation of dual CDK1 and CDK2 inhibitors","volume":"66","author":"Payton","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib149","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.0600447103","article-title":"Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1","volume":"103","author":"Vassilev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118090_bib150","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1038\/onc.2010.290","article-title":"Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16\/18-infected cancer cells","volume":"29","author":"Kreis","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118090_bib151","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.7150\/thno.25487","article-title":"Blocking CDK1\/PDK1\/\u03b2-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma","volume":"8","author":"Wu","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.118090_bib152","article-title":"Inhibition of CDK1 by RO-3306 exhibits anti-tumorigenic effects in ovarian cancer cells and a transgenic mouse model of ovarian cancer","volume":"24","author":"Huang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118090_bib153","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-018-0661-2","article-title":"CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia","volume":"37","author":"Rahaman","year":"2019","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2025.118090_bib154","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib155","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6605479","article-title":"Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells","volume":"102","author":"Johnson","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118090_bib156","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1158\/0008-5472.CAN-05-0882","article-title":"The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases","volume":"65","author":"Emanuel","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118090_bib157","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcp.2019.02.035","article-title":"Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: interaction with carbonyl-reducing enzymes and ABC transporters","volume":"163","author":"Sorf","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118090_bib158","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1021\/jm050267e","article-title":"1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities","volume":"48","author":"Lin","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib159","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/leu.2013.194","article-title":"Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs","volume":"27","author":"Cirstea","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118090_bib160","doi-asserted-by":"crossref","first-page":"35942","DOI":"10.1074\/jbc.M603511200","article-title":"Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A","volume":"281","author":"Canela","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118090_bib161","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cmdc.200800185","article-title":"ATP-noncompetitive inhibitors of CDK-cyclin complexes","volume":"4","author":"Orzaez","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118090_bib162","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1006\/jmbi.2000.3830","article-title":"The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A","volume":"300","author":"Luciani","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118090_bib163","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4161\/cc.6.21.4878","article-title":"Interaction between the Cdk2\/cyclin A complex and a small molecule derived from the pRb2\/p130 spacer domain: a theoretical model","volume":"6","author":"Giordano","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2025.118090_bib164","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jcp.21225","article-title":"Tumor suppressor pRb2\/p130 gene and its derived product Spa310 spacer domain as perspective candidates for cancer therapy","volume":"213","author":"Giordano","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejmech.2025.118090_bib165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.11.019","article-title":"Cyclin B1\/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance","volume":"443","author":"Xie","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118090_bib166","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1089\/ars.2013.5684","article-title":"Cell cycle regulators guide mitochondrial activity in radiation-induced adaptive response","volume":"20","author":"Alexandrou","year":"2014","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2025.118090_bib167","article-title":"Experimental approaches to study mitochondrial localization and function of a nuclear cell cycle kinase, Cdk1","volume":"53417","author":"Candas","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejmech.2025.118090_bib168","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-08-0836","article-title":"AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts","volume":"8","author":"Byth","year":"2009","journal-title":"Mol. Cancer Therapeut."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:32:48Z","timestamp":1772811168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":168,"alternative-id":["S0223523425008554"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118090","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclin-dependent kinase 1 (CDK1) in cancers: from upstream regulation to downstream substrates and therapeutic inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118090"}}